RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

Lin Shen,Ken Kato,Sung-Bae Kim,Jaffer A. Ajani,Kuaile Zhao,Zhiyong He,Xinmin Yu,Yongqian Shu,Qi Luo,Jufeng Wang,Zhendong Chen,Zuoxing Niu,Jong Mu Sun,Chen Yuan Lin,Hiroki Hara,Roberto Pazo-Cid,Christophe Borg,Liyun Li,Aiyang Tao,Eric Van Cutsem

RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

2021

4012Background: Tislelizumab (tisle) monotherapy or plus chemotherapy demonstrated antitumor activity in patients (pts) with solid tumors, including esophageal squamous cell carcinoma (ESCC) (NCT03...

Keywords:

in patient
Medicine
esophageal squamous cell carcinoma
Metastatic Esophageal Squamous Cell Carcinoma
Chemotherapy
Oncology
Internal medicine
antitumor activity
second line treatment
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations